Clinical Scorecard: Long-Term Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: Findings From the 52-Week Phase 3 PaTHway Study
At a Glance
Category
Detail
Condition
Hypoparathyroidism characterized by insufficient parathyroid hormone (PTH) levels causing hypocalcemia and related complications.
Key Mechanisms
TransCon PTH is a sustained-release prodrug of PTH (1-34) providing physiological PTH levels over 24 hours to regulate calcium-phosphate balance.
Target Population
Adults with chronic hypoparathyroidism.
Care Setting
Multicenter clinical trial settings across North America and Europe; applicable to outpatient endocrine care.
Key Highlights
At week 52, 81% of participants achieved normal serum calcium and independence from conventional therapy.
TransCon PTH treatment led to sustained improvements in quality of life, physical functioning, and well-being.
Mean 24-hour urine calcium excretion decreased significantly, and treatment was well tolerated with mostly mild or moderate adverse events.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical features of hypocalcemia, low PTH levels, hyperphosphatemia, and reduced 1,25-dihydroxyvitamin D.
Management
Conventional therapy with active vitamin D and elemental calcium is first-line to raise serum calcium and alleviate symptoms.
Consider PTH replacement therapy when conventional therapy is unsatisfactory due to inadequate biochemical control, symptom burden, or intolerance.
TransCon PTH provides physiological PTH replacement with once-daily subcutaneous administration.
Monitoring & Follow-up
Monitor serum calcium to maintain within target range (lower half or just below reference range).
Monitor 24-hour urine calcium to avoid hypercalciuria and reduce renal risk.
Assess patient-reported outcomes including quality of life and physical functioning.
Risks
Conventional therapy risks include nephrocalcinosis, nephrolithiasis, renal dysfunction, and ectopic calcifications.
Long-term PTH replacement with TransCon PTH showed no trial discontinuations due to adverse events through 52 weeks.
Patient & Prescribing Data
Adults with chronic hypoparathyroidism inadequately controlled or intolerant to conventional therapy.
TransCon PTH enables independence from conventional calcium and active vitamin D supplementation, improves biochemical control, reduces urinary calcium excretion, and enhances quality of life.
Clinical Best Practices
Initiate conventional therapy to manage hypocalcemia symptoms and maintain serum calcium within target range.
Evaluate patients for PTH replacement therapy if conventional treatment is insufficient or causes complications.
Use TransCon PTH as a once-daily subcutaneous injection to provide sustained physiological PTH levels.
Regularly monitor serum and urine calcium, phosphate levels, and patient-reported outcomes to guide therapy adjustments.
Educate patients on potential benefits of PTH replacement including reduced pill burden and improved well-being.
by Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Lisa G Abbott, Lorenz C Hofbauer, Lynn Kohlmeier, Filomena Cetani, Susanne Pihl, Xuebei An, Alden R Smith, Bryant Lai, Jenny Ukena, Christopher T Sibley, Aimee D Shu, Lars Rejnmark
